AI
Commented by Armin Schulz on August 8th, 2025 | 07:10 CEST
Profit with Cloud & AI: Why SAP, MiMedia Holdings, and Palantir must be your focus NOW
Global tech euphoria is reaching new highs in the summer of 2025, driven by much more than just artificial intelligence. Cloud computing, automation, and intelligent systems are the new strategic assets that are revolutionizing markets and shifting revenue streams. Companies are competing for speed, scalability, and data-sovereign solutions in an environment of dizzying valuations and disruptive innovations. Those who choose the right partners now will secure a decisive competitive edge. Three companies stand out: SAP, MiMedia, and Palantir. We take a closer look at their strategies.
Read
Commented by Fabian Lorenz on August 7th, 2025 | 07:30 CEST
Bayer and its billion-dollar problem! Evotec fails to impress analysts! AI stock NetraMark makes a splash!
More positive news for AI insider tip NetraMark. The Company has secured a new customer for its AI platform designed to improve clinical trials. This could bring an end to the stock's sideways trend. Analysts continue to see significant upside. In contrast, analysts are cautious about Bayer's quarterly figures. The surprise stock of the year so far is facing a significant setback. The billion-dollar problems in the US are back on the table, weighing heavily on the stock. And what is Evotec doing? The sale of its site in France is intended to contribute to the Company's profitability. However, this only briefly boosted sentiment on the stock market. In the meantime, the stock has shifted into reverse. Rightly so?
Read
Commented by Armin Schulz on August 7th, 2025 | 07:15 CEST
New Tariff Drama – How Novo Nordisk, Vidac Pharma, and BioNTech are using AI and oncology to counter protectionism
The global pharmaceutical industry is experiencing a historic double revolution in 2025: Artificial Intelligence is accelerating research and personalized therapies, while disruptive US tariffs of up to 250% are reshaping supply chains. These forces are colliding as innovation meets protectionism. The winners are mastering both. They are leveraging digital breakthroughs and circumventing trade barriers through strategic production relocation. Those who invest now stand to benefit from the race to shape the future of global healthcare markets. The area with the most promising growth is oncology. We take a closer look at three exciting companies from the pharmaceutical and biotech industries: Novo Nordisk, Vidac Pharma, and BioNTech.
Read
Commented by Armin Schulz on August 5th, 2025 | 07:30 CEST
Bayer, PanGenomic Health, Novo Nordisk: 3 stocks that could benefit from the USD 330 billion tech tsunami!
In 2025, the healthcare industry is being hit by a tech tsunami. Telemedicine and digital applications are revolutionizing diagnostics and treatment. Driven by AI, regulatory tailwinds, and rising patient demand, the market is exploding. Forecasts predict growth of up to USD 330 billion by 2029. Investors sense billion-dollar opportunities, especially where biotech meets big data and personalized solutions emerge. To benefit from these developments, key players like Bayer, PanGenomic Health, and Novo Nordisk are already positioning themselves today. We take a closer look at all three.
Read
Commented by Armin Schulz on August 5th, 2025 | 07:20 CEST
Evotec, NetraMark Holdings, and Pfizer: How to leverage the hidden biotech boom for returns!
Despite volatile markets, the healthcare sector is showing remarkable resilience. While the sector ETF is weakening, numerous companies are exceeding quarterly forecasts – especially in the biotech segment. Surprising earnings strength and innovative therapies are driving momentum, with even established pharmaceutical giants overcoming patent cliffs. This selectivity creates opportunities: those who identify the right players with disruptive technologies or strategic depth can benefit. Three names are particularly noteworthy here: Evotec, NetraMark Holdings, and Pfizer. We take a look at which companies have potential.
Read
Commented by André Will-Laudien on July 31st, 2025 | 07:15 CEST
AI and biotech – A dream team for returns! Evotec and Novo Nordisk in the spotlight, and NetraMark steps on the gas!
The biotech sector is currently undergoing profound change: big data and artificial intelligence are revolutionizing the way drugs are researched and developed. AI-supported systems help identify molecular target structures more quickly and select active ingredients more precisely. Both start-ups and established companies are increasingly using data-based platforms to shorten development times and make clinical trials more successful. Investors are increasingly directing their capital toward companies that combine biotechnology with modern data analysis. The stock market is ruled by daily madness with figures that are not within the expected range. However, innovative growth markets will remain volatile and attractive at the same time, so bet on the winners!
Read
Commented by Stefan Feulner on July 30th, 2025 | 07:30 CEST
AMD, Veganz Group, and Heidelberger Druckmaschinen AG on a roll
The current trading week promises pure excitement and could bring a surprise or two. In the coming days, nearly 40% of S&P companies will report on their second-quarter performance. Figures from heavyweights such as Microsoft, Meta Platforms, Visa, Apple, and Amazon are likely to keep the markets on their toes. Outside of the flood of figures, several companies shone with outstanding announcements, which investors rewarded with additional purchases.
Read
Commented by Fabian Lorenz on July 24th, 2025 | 07:20 CEST
AI stocks: Buy SAP now? BioNTech surprises! NetraMark beats ChatGPT!
SAP shares performed poorly yesterday. However, the software company is running smoothly and making progress in expanding its AI and cloud business. Is now a good time to get in? Analysts see around 50% upside potential for NetraMark shares. The AI specialist supports Big Pharma in efficient drug development – a billion-dollar market. Now NetraAI has even beaten ChatGPT and DeepSeek! BioNTech is also betting on artificial intelligence. However, the Mainz-based company is currently only making headlines with a change in personnel, but this could change on August 4. Will there be new impetus soon?
Read
Commented by Armin Schulz on July 17th, 2025 | 07:05 CEST
Bayer, NetraMark, Evotec: How AI Research is accelerating returns and could optimize your portfolio
In 2025, the healthcare industry is undergoing a radical transformation driven by AI and advanced technologies. While pharmaceutical giants struggle with cost pressures and regulatory hurdles, algorithms are revolutionizing drug development by decoding clinical data in record time and enabling personalized therapies. In this period of disruption, innovative strength will determine victory or decline. Three companies are at the forefront of this shift: Bayer, with its broad portfolio; NetraMark, leveraging AI-powered data analysis; and Evotec, with its disruptive research collaborations. Find out what is currently driving these stocks.
Read
Commented by André Will-Laudien on July 15th, 2025 | 07:30 CEST
Bitcoin and exchanges in IPO and hysteria mode! AI millions from NetraMark Holdings, Clara Technologies, BitMine, and D-Wave
The recent IPOs on the NASDAQ show just how quickly innovations can materialize. No sooner are they listed than they skyrocket, because what is new must be good! Or is it? From a distance, stock market professionals are beginning to wonder whether everything is still above board. The crypto company BitMine, for example, gained 2,000% within two weeks, only to lose a third of its value after announcing a USD 2 billion capital increase. Clara Technologies debuted on the stock market in January with prices around CAD 0.50. By the end of last week, the share price had exploded to around CAD 16, a 32-fold increase. Our advice: Investors should examine business models very carefully before entering the ring. AI newcomer NetraMark is fully embracing the trends toward digitization and increased accuracy through the use of AI in the clinical trial sector. Where do the opportunities and risks lie for agile investors?
Read